Redbiotec has entered into a perennial collaboration agreement with an undisclosed large pharmaceutical company. Under the contract, Redbiotec will manufacture and re-supply a relevant viral protein complex using the rePAX® technology.
Christian Schaub, CEO of Redbiotec, is very pleased about this development: “This contract reflects our existing good partnership and the unique capabilities of Redbiotec in the development and manufacturing of designer VLPs and protein complexes”. Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.